A Study of Treatment Delivery Preference In People With Kidney Cancer

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Phase changed: Early Phase 1 → Phase 4
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Trial Details
NCT Number NCT07872553
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Renal Cell Carcinoma, Kidney Cancer
Related terms Carcinoma, Renal Cell, Kidney Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov